Neurogene’s (NGNE) “Buy” Rating Reiterated at HC Wainwright

HC Wainwright reiterated their buy rating on shares of Neurogene (NASDAQ:NGNE) in a research note published on Tuesday morning,Benzinga reports. HC Wainwright currently has a $70.00 target price on the stock.

NGNE has been the subject of a number of other research reports. Wall Street Zen cut Neurogene from a “hold” rating to a “sell” rating in a research report on Saturday, December 13th. Weiss Ratings reissued a “sell (d-)” rating on shares of Neurogene in a research note on Wednesday, October 8th. Four analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat.com, the company has a consensus rating of “Hold” and an average target price of $42.50.

Neurogene Stock Down 3.9%

NGNE stock opened at $18.06 on Tuesday. The firm has a 50 day moving average of $20.94 and a two-hundred day moving average of $22.06. Neurogene has a 12 month low of $6.88 and a 12 month high of $37.27. The company has a market capitalization of $279.75 million, a price-to-earnings ratio of -4.39 and a beta of 1.60.

Neurogene (NASDAQ:NGNE) last released its quarterly earnings results on Thursday, November 13th. The company reported ($0.99) earnings per share for the quarter, beating analysts’ consensus estimates of ($1.26) by $0.27. On average, research analysts expect that Neurogene will post -4.27 EPS for the current fiscal year.

Institutional Trading of Neurogene

Hedge funds and other institutional investors have recently added to or reduced their stakes in the business. BNP Paribas Financial Markets lifted its holdings in shares of Neurogene by 89.8% during the third quarter. BNP Paribas Financial Markets now owns 2,067 shares of the company’s stock worth $36,000 after buying an additional 978 shares during the last quarter. PNC Financial Services Group Inc. increased its position in Neurogene by 43.6% during the second quarter. PNC Financial Services Group Inc. now owns 4,055 shares of the company’s stock worth $61,000 after acquiring an additional 1,232 shares during the period. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. raised its stake in Neurogene by 17.9% during the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 6,983 shares of the company’s stock valued at $82,000 after purchasing an additional 1,059 shares during the last quarter. Bridgeway Capital Management LLC bought a new stake in Neurogene in the 3rd quarter valued at $187,000. Finally, Brevan Howard Capital Management LP bought a new stake in Neurogene in the 3rd quarter valued at $223,000. Institutional investors and hedge funds own 52.37% of the company’s stock.

Neurogene Company Profile

Neurogene, Inc is a clinical‐stage biotechnology company specializing in the development of gene therapies for rare neurological diseases. The company’s lead platform employs adeno‐associated virus (AAV) vectors designed to deliver functional copies of disease-causing genes directly to the central nervous system. Neurogene’s pipeline focuses on inherited lysosomal storage disorders, including investigational programs for GM1 and GM2 gangliosidoses, with additional preclinical efforts targeting other monogenic neurodegenerative conditions.

Neurogene’s proprietary AAV9‐based delivery system has been engineered to cross the blood-brain barrier, aiming to provide durable gene expression in affected tissues.